No Data
No Data
Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Shareholder Returns Have Been Favorable, Earning 45% in 3 Years
Guangdong Zhongsheng Pharmaceutical (002317.SZ): The active pharmaceutical ingredient of Proparacaine Hydrochloride has obtained the notification of approval for the listing application of chemical raw materials.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced on September 26th that its wholly-owned subsidiary Guangdong Xianqiang Pharmaceutical Co., Ltd. recently received the approval and issuance of the API procaine hydrochloride by the National Medical Products Administration, with the 'Chemical Raw Materials Market Application Approval Notice.' Procaine hydrochloride is an ester-type surface anesthetic that produces a local anesthetic effect by reducing the instantaneous permeability of neurons to sodium, stabilizing nerve cell membranes, and preventing the generation and conduction of nerve impulses. Procaine hydrochloride eye drops are indicated for ophthalmic surface anesthesia, and are used for: measuring intraocular pressure with a tonometer; suturing and foreign body removal during surgery; as well as conjunctival and corneal scraping.
Some May Be Optimistic About Guangdong Zhongsheng Pharmaceutical's (SZSE:002317) Earnings
Zhongsheng Pharmaceutical: 2024 Semi-Annual Report
Zhongsheng Pharmaceutical: 2024 Semi-Annual Report Summary
Guangdong Zhongsheng Pharmaceutical (002317.SZ): The net income in the first half of the year was 87.4098 million yuan, a decrease of 58.09% compared to the same period last year.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced its semi-annual report for 2024, with revenue of 1.364 billion yuan, a year-on-year decrease of 7.96%; net income attributable to shareholders of the listed company was 87.4098 million yuan, a year-on-year decrease of 58.09%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.174 billion yuan, a year-on-year decrease of 24.28%; basic earnings per share were 0.10 yuan.
No Data
No Data